Combination Antifungal Therapy for Invasive Aspergillosis
|
|
- Candice Wheeler
- 5 years ago
- Views:
Transcription
1 MAJOR ARTICLE Combination Antifungal Therapy for Invasive Aspergillosis Kieren A. Marr, 1,2 Michael Boeckh, 1,2 Rachel A. Carter, 1 Hyung Woo Kim, 1 and Lawrence Corey 1,2 1 Fred Hutchinson Cancer Research Center and 2 University of Washington, Seattle, Washington (See the editorial commentary by Viscoli on pages 803 5) Background. Aspergillosis therapy with amphotericin, azoles, or echinocandins is associated with substantial mortality, ranging from 30% to 80%, depending on the stage of infection and the host s underlying disease. The results of in vitro studies and animal models suggest that combination therapy with azoles and echinocandins may have additive activity against Aspergillus species. Methods. We evaluated the outcomes of patients with aspergillosis who experienced failure of initial therapy with amphotericin B formulations and received either voriconazole ( n p 31 ) or a combination of voriconazole and caspofungin ( n p 16) for salvage therapy. Results. The combination of voriconazole and caspofungin was associated with improved 3-month survival rate, compared with voriconazole alone (hazard ratio [HR], 0.42; 95% confidence interval [CI], ; P p.048). In multivariable models, salvage therapy with the combination of voriconazole and caspofungin was associated with reduced mortality, compared with therapy with voriconazole (HR, 0.28; 95% CI, ; P p.011), independent of other prognostic variables (e.g., receipt of transplant and type of conditioning therapy). The probability of death due to aspergillosis was lowest in patients who received the combination regimen. Conclusions. Randomized trials are warranted to determine whether this combination should be used as primary therapy for aspergillosis. Medical centers worldwide have reported that invasive aspergillosis (IA) has become a leading infection-related cause of death in immunocompromised patients [1 4]. Historically, treatment has been with amphotericin B deoxycholate (AmB-d) or lipid formulations of amphotericin B (LFABs); however, other therapeutic options have recently become available. Voriconazole has been approved for first-line (or primary ) therapy for aspergillosis [5], and caspofungin, which is an echinocandin, has been approved for therapy in patients who experience failure with other antifungal drugs (i.e., approved for salvage therapy) [6]. However, outcomes remain poor, especially in hematopoietic stem cell transplant (HSCT) recipients, with studies demonstrating favorable responses in only 20% 40% of such patients after 3 months of salvage therapy [6, 7]. Received 8 January 2004; accepted 29 April 2004; electronically published 27 August Reprints or correspondence: Dr. Kieren A. Marr, Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, D3-100, Seattle, WA (kmarr@fhcrc.org). Clinical Infectious Diseases 2004; 39: by the Infectious Diseases Society of America. All rights reserved /2004/ $15.00 Azoles and echinocandins target different cellular sites, impacting the fungal cell membrane and the cell wall, respectively. Results of in vitro studies, animal models, and case reports of aspergillosis suggest good outcomes when echinocandins are combined with amphotericin formulations or azoles; however, no comparative clinical data have been published [8 14]. Here, we compared the outcomes of salvage therapy for aspergillosis with the combination of voriconazole and caspofungin, compared with voriconazole alone, in a sequential cohort of patients in our center (Fred Hutchinson Cancer Research Center [FHCRC]; Seattle, WA). METHODS Informed consent was obtained from patients or their parents or guardians, and this retrospective review was approved by the FHCRC Institutional Review Board. Patients who developed pulmonary aspergillosis after reciept of HSCT or cytotoxic chemotherapy for a hematologic malignancy at FHCRC were identified by review of microbiology, histopathology, and infectioncontrol records [1, 15]. Only patients with aspergillosis Combination Therapy for Aspergillosis CID 2004:39 (15 September) 797
2 defined as proven or probable according to standardized composite criteria were included [16]. During the review period ( ), standard practice guidelines that were developed by the infectious diseases program were used to direct antifungal therapy. Practice was to initiate therapy with AmB-d ( 1 mg/kg q.d.) and to change to voriconazole (6 mg/kg, followed by 4 mg/kg b.i.d.) for salvage therapy. A change to a salvage regimen was indicated by progressive infection, intolerance to the initial regimen, or renal dysfunction (creatinine clearance of!30 ml/min or creatinine level of 12.5 mg/ml) after 7 days of amphotericin-based therapy. Patients who had preexisting renal dysfunction or a history of AmB-d intolerance could receive LFABs (amphotericin B lipid complex or liposomal amphotericin B, both at a dosage of 5 mg/kg q.d.) prior to receipt of voriconazole as salvage therapy. In February 2001, practice was altered such that caspofungin was administered (70 mg on the first day of therapy, followed by 50 mg q.d.) in combination with voriconazole (6 mg/kg, followed by 4 mg/kg b.i.d.) for salvage therapy. Demographic and treatment data were obtained by review of computerized databases and patient charts. An investigator blinded to treatment arm examined discharge summaries and autopsy records to determine cause of death and indication for salvage therapy. Patient-identifying and therapy data were removed from documents to mask treatment arm for this review. Because aspergillosis-related deaths were an important endpoint, patients with graft-versus-host disease (GVHD) who died with infection were considered to have died due to the infection, not due to GVHD. However, to minimize bias introduced by receipt of additional myelosuppressive therapies, patients with relapsed malignancy were considered to have died due to relapse, not due to the infection. Other outcomes analyzed included survival for 3 months after the diagnosis of aspergillosis and survival for 3 months after the start of salvage therapy. To evaluate the relative safety of the salvage regimens, median total bilirubin, aspartate aminotransferase, and creatinine levels were compared during the course of salvage therapy (from initiation until 90 days after the start of salvage therapy). Survival was estimated with Kaplan-Meier curves [17]. Multivariable analysis was performed to determine the impact of antifungal therapy on 3-month survival. In overall Cox proportional-hazard regression models, candidate variables included antifungal therapy, underlying risk (no transplant received vs. autologous or allogeneic HSCT received), stage of aspergillosis (disseminated vs. pulmonary), and type of antifungal drug administered for primary therapy (AmB-d vs. LFAB). Because prior studies found that outcomes for allogeneic HSCT recipients are dependent on transplant type and GVHD therapy [4, 18], additional models were performed only among allogeneic HSCT recipients, including the variables of conditioning therapy (myeloablative vs. nonmyeloablative) and maximum corticosteroid dose ( 2 mg/kg q.d.). Variables with a P value of.25 were entered into the model and sequentially eliminated in a stepwise backward fashion, with a significance level of!.05 as the criterion for inclusion. RESULTS We analyzed the outcomes for 47 patients who acquired confirmed (proven or probable) aspergillosis from 1997 through Forty-one patients developed infection after receipt of HSCTs, and 6 developed infection after receiving cytotoxic chemotherapy. Patients were well matched with regard to age, sex, underlying disease, type of conditioning therapy, and maximum corticosteroid doses received for GVHD (table 1). The majority of patients in both the voriconazole and combination salvage therapy arms received salvage therapy because they experienced clinical failure (not because of intolerance); however, there was a trend for a greater proportion of patients in the combination therapy arm to have received salvage therapy for progressive aspergillosis ( P p.13, by Fisher s exact test). There were slightly more patients who received combination salvage therapy for extrapulmonary disseminated and proven aspergillosis; however, differences were not statistically significant. The median duration and types of primary antifungal therapy were not significantly different (table 1). Survival after diagnosis of IA among patients receiving voriconazole alone was compared with survival among those receiving the combination regimen. Because salvage therapy was initiated at different times relative to the diagnosis of aspergillosis, we evaluated outcomes relative to both the day of diagnosis and the start of salvage therapy. Overall survival at 3 months after the day of diagnosis of aspergillosis was highest among patients who received the combination regimen (figure 1; P p.048). Similarly, 3-month survival after the start of salvage therapy was greatest among the group of patients who received the combination regimen (hazard ratio [HR], 0.43; 95% CI, ; P p.050). We repeated the analysis after excluding several patients in both treatment groups (4 in the monotherapy group and 2 in the combination therapy group) who received!7 days of salvage therapy; in this limited cohort, there was still a trend to an increased survival rate in the combination therapy group (HR, 0.38; 95% CI, ; P p.058). Finally, the probability of death due to aspergillosis was lower in patients who received combination therapy, compared with voriconazole alone (figure 2; P p.024). Results of the univariate Cox regression model to identify risks for death are shown in table 2. Multivariable models were performed to determine whether the improved survival after combination therapy was independent of other variables. Among the entire cohort of patients (table 3), combination salvage therapy was associated with reduced mortality relative to voriconazole alone (HR, 0.27; 95% CI, ; P p 798 CID 2004:39 (15 September) Marr et al.
3 Table 1. Demographic and clinical characteristics of patients receiving salvage therapy with either voriconazole alone (voriconazole group) or voriconazole and caspofungin (combination group). Variable Voriconazole group (n p 31) Combination group (n p 16) P Age, median years (range) 49 (16 66) 45 (18 66).77 Female sex 17 (55) 12 (75).22 Type of HSCT Autologous 3 (10) 1 (6).36 Allogeneic HLA-MR 11 (35) 6 (38) MM-URD 15 (48) 5 (31) Other a 2 (6) 4 (25) Conditioning therapy b Myeloablative 27 (87) 12 (75).42 Nonmyeloablative 4 (13) 4 (25) Underlying disease c AML 5 (16) 6 (38).12 CML 9 (29) 1 (6) MDS 8 (26) 2 (13) MM 3 (10) 1 (6) NHL 3 (10) 1 (6) Other 3 (10) 5 (3) Maximum corticosteroid dose, mg/kg per day (61) 8 (50) (39) 8 (50) Stage of aspergillosis d Pulmonary only 28 (90) 12 (75).21 Disseminated 3 (10) 4 (25) Certainty of diagnosis e Proven 18 (58) 12 (75).34 Probable 13 (42) 4 (25) Indication for salvage therapy f Progression of infection 20 (71) 14 (93).13 Renal insufficiency/other g 8 (29) 1 (7) Duration of therapy, median days (range) Primary therapy 14 (4 59) 14 (2 334).42 Salvage therapy 33 (2 205) 68 (3 248).14 Type of primary therapy AmB-d 13 (42) 4 (25).34 LFAB 18 (58) 12 (75) NOTE. Data are no. (%) of patients, unless otherwise indicated. AmB-d, amphotericin B deoxycholate; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; HLA- MR, human leukocyte antigen matched related donor; HSCT, hematopoietic stem cell transplant; LFAB, lipid formulations of amphotericin B; MDS, myelodysplastic syndrome; MM, multiple myeloma, MM-URD, human leukocyte antigen mismatched or unrelated donor; NHL, non-hodgkin lymphoma. a Indicates patients who had not yet received HSCT but had received cytotoxic chemotherapy for an underlying malignant disorder. b Administered as described elsewhere [27, 28]. c The most common other diagnoses include aplastic anemia (2 patients), acute and chronic lymphocytic leukemia (2), and Hodgkin disease (1). d Stage of aspergillosis at time of diagnosis; disease was considered disseminated (i.e., extrapulmonary) if proven by histological examination or probable by radiographic appearance. e Defined according to published consensus criteria [16]. f Indication for change of therapy was not available for 3 patients in the voriconazole group and 1 patient in the combination group. g Other indicates prior intolerance to amphotericin B formulations (attributed to allergic reactions in 1 patient).
4 Figure 1. Kaplan-Meier probability of survival after diagnosis of proven or probable invasive aspergillosis (IA) in patients treated with voriconazole alone (voriconazole group) or voriconazole with caspofungin (combination group). P p.048, calculated from the likelihood ratio test using Cox regression. The number of patients evaluable during each time period is indicated..008). Patients who had not yet received a transplant had an increased risk for death, although the number of such patients was small (HR, 3.8; 95% CI, ; P p.032). Use of nonmyeloablative conditioning therapy appeared to reduce the 90- day mortality according to the univariate analysis, but the effect was not significant after adjusting for antifungal therapy and receipt of transplant (HR, 0.36; 95% CI, ). After restricting the model to allogeneic HSCT recipients, receipt of combination therapy was again associated with reduced mortality, compared with voriconazole alone (HR, 0.25; 95% CI, ; P p.029). In this multivariable model, there was again a trend to increased survival in patients who received nonmyeloablative conditioning therapy (HR, 0.44; 95% CI, ; P p.22) when controlling for antifungal therapy. Stage of aspergillosis was not predictive of survival in multivariable models. Combination therapy was associated with a decreased risk of death, independent of the type of primary therapy (AmB-d vs. LFAB), which was not significant in any model. The relative safety of the 2 salvage regimens was assessed by comparing several laboratory parameters of hepatic and renal function during the first 3 months of salvage therapy. There was no difference in total bilirubin level between patients receiving voriconazole (median, 4.1 mg/ml; range, mg/ml) and those receiving combination therapy (median, 3.8 mg/ml; range, mg/ml). Similarly, aspartate aminotransferase levels did not differ during salvage therapy with voriconazole (median, 45.6 U/L; range, U/L), compared with the combination of drugs (median, 34.2 U/L; range, U/L). There was also no difference in serum creatinine level in recipients of voriconazole (median, 2.2 mg/dl; range, mg/dl), compared with combination therapy (median, 1.5 mg/dl; range, mg/dl). DISCUSSION Comparison of the most objective parameter of therapeutic success survival showed that the combination of voriconazole and caspofungin was associated with better outcomes, compared with voriconazole administered alone, for patients receiving salvage therapy to treat aspergillosis. These data support the use of the combination regimen in treating patients who require salvage therapy, but given the retrospective nature of this study, a randomized trial will be necessary to determine whether combination regimens will be effective for primary therapy for aspergillosis. Combination antifungal therapy has been of interest because of the poor outcomes associated with treatment with either azole antifungals or amphotericin B formulations alone, especially in HSCT recipients. Although combination regimens that include amphotericin formulations and azoles have not Figure 2. Probability of death due to invasive aspergillosis (IA) after diagnosis of IA in patients treated with a salvage therapy regimen of voriconazole alone (voriconazole group) or voriconazole with caspofungin (combination group). Patients with IA and graft-versus-host disease were considered to have died due to IA; to minimize bias from receipt of myelosuppressive therapies, patients with relapsed malignancy were considered to have died due to relapse [25]. P p.024, calculated from the test for comparing groups in the presence of competing risks [26]. The number of patients evaluable during each time period is indicated. 800 CID 2004:39 (15 September) Marr et al.
5 Table 2. Risk of death in patients with invasive aspergillosis receiving salvage therapy with either voriconazole alone or a combination of voriconazole and caspofungin, according to univariate Cox regression models. Variable HR (95% CI) P Antifungal therapy received Voriconazole Combination 0.42 ( ) Receipt of transplant Yes No 1.9 ( ) Stage of aspergillosis Pulmonary only Disseminated 0.35 ( ) Primary therapy received LFAB AmB-d 1.1 ( ) Conditioning therapy received Myeloablative Nonmyeloablative 0.30 ( ) Maximum corticosteroid dose, mg/kg per day ( ) NOTE. AmB-d, amphotericin B deoxycholate; HR, hazard ratio; LFAB, lipid formulation of amphotericin B. resulted in favorable responses in either in vitro studies or animal models [19], this combination has frequently been used as a result of clinical desperation. Regimens that combine azoles or amphotericin with echinocandins may be more compelling than others because of their unique mechanisms of action. Recent in vitro studies and animal models evaluating therapy with caspofungin combined with amphotericin [8], voriconazole [9, 10], or ravuconazole [20] demonstrated favorable responses against Aspergillus species. Cases of successful therapy using caspofungin and itraconazole [12] and caspofungin and LFABs [11, 13, 14] have also been reported. In this comparative analysis of clinical outcomes, we observed a survival advantage in patients treated with the combination of voriconazole and caspofungin, compared with voriconazole alone. Responses were not a function of primary therapy, because patients in both arms received equivalent durations and types of amphotericin B formulations. Multivariable analyses confirmed that combination therapy was associated with improved survival, even though a greater proportion of patients had disseminated and/or progressive aspergillosis at baseline in the combination arm than in the monotherapy arm. The multivariable analyses attempted to control for differences in host variables that may have changed over the time period during which the outcomes were observed. To this end, the impact of antifungal therapies appeared independent of the type of conditioning therapy and the receipt of corticosteroids, both of which are factors that have Table 3. Risk of death in patients with invasive aspergillosis receiving salvage therapy with either voriconazole alone or a combination of voriconazole and caspofungin, according to multivariate Cox regression models. Cox regression, variable HR (95% CI) P Bivariate Antifungal therapy received Voriconazole Combination 0.27 ( ) Receipt of transplant Yes No 3.8 (1.2 12) Trivariate Antifungal therapy received Voriconazole Combination 0.28 ( ) Receipt of transplant Yes No 3.2 (1.0 10) Conditioning therapy received Myeloablative Nonmyeloablative 0.36 ( ) NOTE. HR, hazard ratio. been shown to be important prognostic variables in other studies [4, 21 23]. However, the retrospective and noncontemporaneous nature of this comparison limits the conclusions that can be drawn, because other changes in transplantation or supportivecare practices could account for the differences in outcome. Some of these variables may not be apparent or quantifiable in this small observational study. In this study, the 3-month survival rate of patients treated with voriconazole was 40%, which does not differ from the survival rate of patients treated at our institution in earlier years [15]. Assigning attributable mortality in patients with opportunistic infections is difficult, given the presence of multiple comorbidities. Cause-of-death analysis revealed that 20% 50% of patients died as a result of aspergillosis within 3 months after diagnosis. The finding that combination therapy was associated with a decreased mortality rate suggests that a large proportion of poor outcomes can be ameliorated with improved antifungal regimens for both prevention and therapy. The persistently high mortality rate associated with aspergillosis, even among patients treated with voriconazole for salvage therapy, prompted our exploration of combination therapy. Although we evaluated outcomes in a relatively large group of patients and made efforts to equalize the composition of treatment arms with use of both entry criteria and multivariable models, the conclusions of this study are limited by its retrospective design. An appropriately powered randomized trial is warranted to determine whether this combination would be optimal first-line therapy for aspergillosis. Such a trial is im- Combination Therapy for Aspergillosis CID 2004:39 (15 September) 801
6 perative, given the added toxicities, drug interactions, and costs that may be encountered when administering combinations of antifungal drugs. Design of such a trial will require careful consideration; as reviewed in a recent editorial, 570 evaluable subjects will be required in order to show a 10% difference in survival with use of predictions based on data for patients receiving voriconazole monotherapy [24]. The survival advantage we observed may support the use of the combination regimen in the select group of patients who are experiencing treatment failure with other therapies. For these patients, it appears that the combination regimen, compared with voriconazole monotherapy, is at least not associated with worse outcomes. Acknowledgments We acknowledge the efforts of the Fred Hutchinson Cancer Research Center Program in Infectious Diseases (Seattle, WA) research nurses and database coordinators, as well as the efforts of clinicians, microbiologists, and pathologists, who have assisted in the conduct of the clinical trials and the formation of the fungal infection database. Financial support. National Institutes of Health (grants CA18029 and CA15704). Conflict of interest. K.A.M. has served as a consultant for Pfizer, Merck, Fujisawa, Enzon, Ortho Biotechnologies, Schering Plough, and Vicuron. M.B. has served as a consultant for Pfizer and Enzon. All other authors: No conflict. References 1. Marr K, Carter R, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: Grow W, Moreb J, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marr Transplant 2002; 29: Benjamin DK Jr, Miller WC, Bayliff S, Martel L, Alexander KA, Martin PL. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002; 21: Ribaud P, Chastang C, Latge J, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: Cancidas (caspofungin acetate) for injection [package insert]. Whitehouse Station, NJ: Merck; Available at: medwatch/safety/2004/march04.htm#/cancidas. Accessed 1 December Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: Arikan S, Lozano-Chiu M, Paetznick V, Rex J. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of aspergillus spp. Antimicrob Agents Chemother 2002; 46: Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: Lum L, Turco T, Leone J. Combination therapy with caspofungin and amphotericin B lipid complex. Am J Health Syst Pharm 2002; 1: Rubin M, Carroll K, Cahill B. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002; 34: Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: Aliff TB, Maslak PG, Jurcic JG, et al. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: Ascioglu A, Rex J, DePauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958: Junghanss C, Marr K, Carter R, et al. Incidence of bacterial and fungal infections after nonmyeloablative compared to myeloablativeallogeneic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 2002; 8: Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995; 39: Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: Wheat L. Combination antifungal therapy for aspergillosis: is it needed, and which combination? J Infect Dis 2003; 187: Marr K, Seidel K, Slavin M, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-relateddeath in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statistics 1988; 16: McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: Clift R, Buckner C, Thomas E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclosphosphamide and total body irradiation with busulfan and cyclosphosphamide. Blood 1994; 84: CID 2004:39 (15 September) Marr et al.
No Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationInvasive aspergillosis (IA) is a leading cause of infectious death in
292 Efficacy and Toxicity of Caspofungin in Combination with Liposomal Amphotericin B as Primary or Salvage Treatment of Invasive Aspergillosis in Patients with Hematologic Malignancies Dimitrios P. Kontoyiannis,
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationDepartment of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2
Case Reports in Transplantation Volume 2012, Article ID 672923, 4 pages doi:10.1155/2012/672923 Case Report Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem
More informationFactors Associated with Mortality in Transplant Patients with Invasive Aspergillosis
MAJOR ARTICLE Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis John W. Baddley, 1,2 David R. Andes, 3 Kieren A. Marr, 4 Dimitrios P. Kontoyiannis, 6 Barbara D. Alexander,
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationDifficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies
Difficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies Amar Safdar The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Key Words.
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationII Raad, HA Hanna, M Boktour, Y Jiang, HA Torres, C Afif, DP Kontoyiannis and RY Hachem
(2008) 22, 496 503 & 2008 Nature Publishing Group All rights reserved 0887-6924/08 $30.00 www.nature.com/leu ORIGINAL ARTICLE Novel antifungal agents as salvage therapy for invasive aspergillosis in patients
More informationCombination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient
case report Combination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient Andres Beiras-Fernandez, 1 * Amir K. Bigdeli, 1 * Thomas Nickel, 2 Sebastian Michel, 1 Peter
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationAbstract. Introduction
ORIGINAL ARTICLE MYCOLOGY The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion Y.-Q. Sun, L.-P. Xu,
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationHow Can We Tailor Antifungal Therapy?
How Can We Tailor Antifungal Therapy? Russell Lewis Infections Diseases Unit Department of Medical Sciences and Surgery S.Orsola Malpighi Hospital University of Bologna Most Common Infectious Diagnosis
More informationEMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationMAJOR ARTICLE. Carol Garcia-Vidal, 1,4 Arlo Upton, 1 Katharine A. Kirby, 1 and Kieren A. Marr 1,2,3
MAJOR ARTICLE Epidemiology of Invasive Mold Infections in Allogeneic Stem Cell Transplant Recipients: Biological Risk Factors for Infection According to Time after Transplantation Carol Garcia-Vidal, 1,4
More informationRisks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
More informationInvasive Aspergillosis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Analysis
BJID 2008; 12 (October) 385 Invasive Aspergillosis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Analysis Viviane Maria Hessel Carvalho-Dias 1, Caroline Bonamin Santos Sola 1, Clóvis
More informationOliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research
Management of Confirmed Aspergillosis Oliver A. Cornely 1 Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2 Centre for Clinical Research University of Cologne
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationNewer Combination Therapies
Newer Combination Therapies William J. Steinbach, MD Associate Professor of Pediatrics, Molecular Genetics & Microbiology Pediatric Infectious Diseases Duke University Medical Center Combination Therapy
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationAntifungal Therapy in Leukemia Patients
Antifungal Therapy in Leukemia Patients UPDATE ECIL 4, 6 September 2011 Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier UPDATE ECIL 4, 2011 UPDATE
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationHOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?
HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? EORTC IFICG START Look for Help? MORTALITYASSOCIATED WITH INVASIVE ASPERGILLOSIS Lin et al. Clin Infect Dis 2001;32:358 100 % 50 n = 178 0 0 60 120
More informationEffect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation Authors: Hirohisa Nakamae, 1 Katharine A. Kirby, 1 Brenda M. Sandmaier, 1,2
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationAbstract. Introduction. Editor: M. Paul
ORIGINAL ARTICLE MYCOLOGY Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation
More informationFactors Associated with Overall and Attributable Mortality in Invasive Aspergillosis
MAJOR ARTICLE Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis Yasmine Nivoix, 1 Michel Velten, 7 Valérie Letscher-Bru, 2 Alireza Moghaddam, 3 Shanti Natarajan-Amé,
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationInvasive aspergillosis (IA) has emerged as a major cause of morbidity. Aspergillus terreus
1594 Aspergillus terreus An Emerging Amphotericin B Resistant Opportunistic Mold in Patients with Hematologic Malignancies Ray Y. Hachem, M.D. 1 Dimitrios P. Kontoyiannis, M.D., Sc.D. 1 Maha R. Boktour,
More informationPoor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment
Biology of Blood and Marrow Transplantation 8:155-160 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte
More informationForm 2046 R3.0: Fungal Infection Pre-HSCT Date
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationSCIENTIFIC DISCUSSION
London, 14 July 2004 Product name: Cancidas Procedure No. EMEA/H/C/379/II/17 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationAntifungal prophylaxis in haematology patients: the role of voriconazole
REVIEW 10.1111/j.1469-0691.2012.03772.x Antifungal prophylaxis in haematology patients: the role of voriconazole Y. Hicheri 1, G. Cook 2 and C. Cordonnier 1 1) Service d Hématologie Clinique, Assistance
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationEvaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 941-946, 2014 Evaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B EISEKI USAMI 1, MICHIO KIMURA 1, TETSUFUMI
More informationAmphotericin B Lipid Complex (Abelcet ) 05/06
Amphotericin B Lipid Complex (Abelcet ) Structure and Activity AMB : DMPC : DMPG lipid complex, 10:7:3 mol:mol ribbon-like lipid structures, 1.6-11 µm in diameter binds to ergosterol disturbance of cell
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Noxafil) Reference Number: AZ.CP.PHAR.30 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this
More informationBB&MT. Biology of Blood and Marrow Transplantation 10: (2004) 2004 American Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 10:645-652 (2004) 2004 American Society for Blood and Marrow Transplantation 1083-8791/04/1009-0007$30.00/0 doi:10.1016/j.bbmt.2004.06.003 Incidence of Invasive
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationAmphotericin B Colloidal Dispersion vs. Amphotericin B as Therapy for Invasive Aspergillosis
635 Amphotericin B Colloidal Dispersion vs. Amphotericin B as Therapy for Invasive Aspergillosis Mary H. White, Elias J. Anaissie, Shimon Kusne, John R. Wingard, John W. Hiemenz, Alan Cantor, Marc Gurwith,
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationDose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation
(2005) 19, 171 175 & 2005 Nature Publishing Group All rights reserved 0887-6924/05 $30.00 www.nature.com/leu KEYNOTE ADDRESS Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell
More informationInvasive aspergillosis in pediatric patients
Current Medical Research and Opinion ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: http://www.tandfonline.com/loi/icmo20 Invasive aspergillosis in pediatric patients William J. Steinbach
More informationOutline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT
Comorbidities before Allogeneic Hematopoietic Cell Transplantation (HCT) The HCT-specific Comorbidity Index (HCT-CI) Mohamed Sorror, M.D., M.Sc. FHCRC Seattle, WA Outline Pretransplant Essential data Why
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationTrends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients. Saturday, April 18, 2015 Charlottetown, P.E.I.
Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients Saturday, April 18, 2015 Charlottetown, P.E.I. Moderator & Speaker: Shariq Haider MD, FRCPC, FACP, CCST(UK), DTMH(UK) Professor
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationASBMT and Marrow Transplantation
Biol Blood Marrow Transplant 19 (2013) 661e675 Brief Articles Improved Survival over the Last Decade in Pediatric Patients Requiring Dialysis after Hematopoietic Cell Transplantation American Society for
More informationTailored Antifungal Modification in Breakthrough Mold Infections. Russell E. Lewis University of Bologna
Tailored Antifungal Modification in Breakthrough Mold Infections Russell E. Lewis University of Bologna 45 year-old patient with AML and documented pulmonary aspergillosis during remissioninduction chemotherapy
More informationApproach to the Transplant Patient. Amy Musiek, MD AAD Annual Meeting 2018
Approach to the Transplant Patient Amy Musiek, MD AAD Annual Meeting 2018 Disclosures Actelion: speaker, advisory board, investigator Elorac: investigator Kyowa: investigator, advisory board Seattle genetics:
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationInvasive Aspergillosis in Steroid-Treated Patients
Invasive Aspergillosis in Steroid-Treated Patients Dimitrios P. Kontoyiannis, MD, ScD Professor of Medicine Department of Infectious Diseases Infection Control and Employee Health PMN damaging Aspergillus
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More informationInfection post transplant Central nervous system aspergillosis in allogeneic stem cell transplant recipients
(2003) 31, 191 196 & 2003 Nature Publishing Group All rights reserved 0268-3369/03 $25.00 www.nature.com/bmt Infection post transplant Central nervous system aspergillosis in allogeneic stem cell transplant
More informationEfficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy
MAJOR ARTICLE Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy Johan Maertens, Issam Raad, 2 George
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationRiches Usher Dilemmas: Antifungal Therapy in Invasive Aspergillosis
Biology of Blood and Marrow Transplantation 11:77-84 (2005) 2005 American Society for Blood and Marrow Transplantation 1083-8791/05/1102-0001$30.00/0 doi:10.1016/j.bbmt.2004.11.021 Riches Usher Dilemmas:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vfend) Reference Number: AZ.CP.PHAR.39 Effective Date: 11.16.16 Last Review Date: 09.11.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationPre-transplant Neutropenia Is Associated with Poor Risk Cytogenetic Features and
Pre-transplant Neutropenia Is Associated with Poor Risk Cytogenetic Features and Increased Infection-related Mortality in Patients with Myelodysplastic Syndromes Bart L. Scott 1, 2, J.Y. Park 3, H. Joachim
More informationLondon New Drugs Group APC/DTC Briefing
London New Drugs Group APC/DTC Briefing Posaconazole for invasive fungal infections Contents Background 2 Dosing Information 3 Clinical evidence for treatment of infections 3 Clinical evidence for prophyactic
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationLiposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients
ORIGINAL ARTICLE MYCOLOGY Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients K. Bochennek 1, L. Tramsen 1, N. Schedler 1, M. Becker 1, T. Klingebiel
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationIsavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57:
Priv.-Doz. Dr. med. Maria J.G.T. Vehreschild Department I of Internal Medicine Clinical Trials Unit II Infectious Diseases Research Group Clinical Microbiome Isavuconazole 09.07.2017 Maria J.G.T. Vehreschild
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationInvasive aspergillosis: Is treatment with inexpensive amphotericin B cost-saving if expensive voriconazole is only used on demand?
Original article Peer reviewed article SWISS MED WKLY 25;135:624 63 www.smw.ch 624 Invasive aspergillosis: Is treatment with inexpensive amphotericin B cost-saving if expensive voriconazole is only used
More information